

**ASSESSING THE PROGNOSTIC SIGNIFICANCE OF CD8<sup>+</sup> T-  
CELL COUNTS IN DETERMINING THE RISK OF  
MYOCARDIAL INFARCTION IN THE SETTING OF HIV  
INFECTION**

by

**Oluwatosin Abimbola Badejo**

MBBS, University of Maiduguri, Nigeria, 2008

Submitted to the Graduate Faculty of  
Department of Biostatistics  
Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of  
Master of Public Health

University of Pittsburgh

2013

UNIVERSITY OF PITTSBURGH  
GRADUATE SCHOOL OF PUBLIC HEALTH

This thesis was presented

by

Oluwatosin Abimbola Badejo

It was defended on

April 11, 2013

and approved by

**Thesis Advisor:**

John W. Wilson, PhD  
Assistant Professor  
Department of Biostatistics, Graduate School of Public Health  
University of Pittsburgh

**Committee Member:**

Chung-Chou (Joyce) Ho-Chang, PhD  
Associate Professor  
Division of General Internal Medicine, School of Medicine  
Department of Biostatistics, Graduate School of Public Health  
University of Pittsburgh

**Committee Member:**

Matthew S. Freiberg, MD, MSc  
Associate Professor  
Division of General Internal Medicine, School of Medicine  
Department of Epidemiology, Graduate School of Public Health  
University of Pittsburgh

Copyright © by Oluwatosin A. Badejo

2013

**ASSESSING THE PROGNOSTIC SIGNIFICANCE OF CD8<sup>+</sup> T-  
CELL COUNTS IN DETERMINING THE RISK OF  
MYOCARDIAL INFARCTION IN THE SETTING OF HIV  
INFECTION**

Oluwatosin Abimbola Badejo, MPH

University of Pittsburgh, 2013

**ABSTRACT**

There is a growing body of research to suggest that Human Immunodeficiency Virus (HIV) infection is associated with an increased risk for myocardial infarction (MI) although the underlying processes remain unclear. An assessment of MI risk using a commonly-available measure of the immune status is therefore of Public Health importance. CD8<sup>+</sup> and CD4<sup>+</sup> T-cell counts are periodically measured in the routine management of HIV-infected patients. However, CD8<sup>+</sup> T-cell counts are often not reported or are simply incorporated into the calculation of a CD4<sup>+</sup>/CD8<sup>+</sup> ratio. Total CD8<sup>+</sup> T-cell counts have been shown to be associated with an increased risk for MI in at least one recent study. A few other studies have examined this association indirectly by using the CD4<sup>+</sup>/CD8<sup>+</sup> ratio, but only considered MI surrogates (e.g. subclinical coronary atherosclerosis) as an outcome. Also, measuring cell-surface markers of CD8<sup>+</sup> T-cell activation and HIV-specific CD8<sup>+</sup> T cell counts is costly and often not requested in the routine management of HIV infection.

This study investigated the association between total CD8<sup>+</sup> T-cell counts and MI risk among a large cohort of HIV-uninfected and HIV-infected Veterans. Using Cox proportional

hazard regression models, the results suggest that MI risk is associated with a high CD8<sup>+</sup> T-cell count of  $\geq 1066$  cells/ mm<sup>3</sup> (Adjusted HR = 1.82,  $P < 0.001$ , 95% CI: 1.46 to 2.28). They also suggest that the risk for MI posed by total CD8<sup>+</sup> T-cell counts should be interpreted in the context of CD4<sup>+</sup> T-cell clinical cut-points, or the overall immune status. The degree of MI risk in the cohort differed depending on the level of the immunosuppression. Total CD8<sup>+</sup> T cell-counts seemed to modestly improve the risk stratification provided by CD4<sup>+</sup> T-cell clinical cut-points, though the mechanisms are still unclear. Future studies will be instrumental in understanding the role of the immune system in MI risk prediction.

## TABLE OF CONTENTS

<b>ACKNOWLEDGEMENTS .....</b>	<b>XI</b>
<b>1.0 INTRODUCTION.....</b>	<b>1</b>
<b>1.1 BACKGROUND .....</b>	<b>1</b>
<b>1.2 MOTIVATION FOR THE STUDY.....</b>	<b>3</b>
<b>1.3 PURPOSE OF THE STUDY .....</b>	<b>4</b>
<b>2.0 METHODS .....</b>	<b>5</b>
<b>2.1 STUDY POPULATION .....</b>	<b>5</b>
<b>2.2 DEPENDENT VARIABLE.....</b>	<b>6</b>
<b>2.3 PREDICTOR VARIABLES.....</b>	<b>7</b>
<b>2.3.1 Primary Independent Variable.....</b>	<b>7</b>
<b>2.3.2 Covariates .....</b>	<b>8</b>
<b>2.3.2.1 Blood pressure.....</b>	<b>8</b>
<b>2.3.2.2 Lipid levels.....</b>	<b>8</b>
<b>2.3.2.3 Obesity.....</b>	<b>9</b>
<b>2.3.2.4 Renal Disease.....</b>	<b>9</b>
<b>2.3.2.5 Diabetes .....</b>	<b>9</b>
<b>2.3.2.6 Smoking History.....</b>	<b>9</b>
<b>2.3.2.7 Substance Abuse.....</b>	<b>10</b>

2.3.2.8	Hepatitis C Virus Infection .....	10
2.3.2.9	Hemoglobin Concentration .....	10
2.3.2.10	Covariates Specific to HIV-Infected Veterans .....	10
2.4	STATISTICAL METHODS AND ANALYSES .....	11
2.5	REGRESSION MODELS.....	12
2.6	MISSING DATA.....	13
3.0	RESULTS .....	14
3.1	BASELINE CHARACTERISTICS .....	14
3.2	RATES OF MI.....	17
3.3	ESTIMATES OF SURVIVAL FUNCTION .....	19
3.4	ESTIMATED MI RISK .....	21
4.0	DISCUSSION .....	32
5.0	CONCLUSION.....	39
	APPENDIX: SUPPLEMENTAL TABLES AND FIGURES .....	40
	BIBLIOGRAPHY .....	45

## LIST OF TABLES

Table 1. Baseline Characteristics of HIV-Infected and Matched HIV-Uninfected Veterans, Stratified by CD8 <sup>+</sup> T-cell Level.....	15
Table 2. MI Rates compared with Mortality Rates, by Baseline CD8 <sup>+</sup> T-cell Level (per 10,000 person years).....	17
Table 3. MI Rates compared with Mortality Rates by Baseline CD4 <sup>+</sup> T-cell Clinical Cut-points and Baseline CD8 <sup>+</sup> T-cell Level (per 10,000 person years) .....	18
Table 4. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8 <sup>+</sup> T-cell levels and MI.....	23
Table 5. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8 <sup>+</sup> T-cell levels and MI for persons below or above middle age (50 years) .....	26
Table 6. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8 <sup>+</sup> T-cell levels and MI in HIV-Infected Veterans only.....	29
Table A.1. Missing Data for Baseline Variables of HIV-uninfected and HIV-infected Veterans	40
Table A.2. Number of Persons at Risk at Specific Time Points during the Follow-up Period (Risk Tables).....	41
Table A.3. Test statistics, Degrees of Freedom and <i>P</i> values for the Equality of the Survival Functions for various participant groups .....	42



Table A.4. Test statistics of Scaled Schoenfeld Residuals, Degrees of Freedom and  $P$  values for the tests of Proportional-Hazards assumptions for various proportional-hazards models using different functions of time ..... 43

## LIST OF FIGURES

Figure 1. Natural History of HIV.....	2
Figure 2. Rates of MI and Rates of All-cause mortality by T-cell count.....	19
Figure 3. Graph of Kaplan-Meier survival estimates of MI development for different HIV/ CD8 <sup>+</sup> T-cell strata .....	20
Figure 4. Graph of Kaplan-Meier survival estimates of MI development for different HIV/ CD8 <sup>+</sup> T-cell strata by CD4 <sup>+</sup> T-cell level.....	21
Figure A.1. Log-log plot testing Proportional Hazards Assumptions for three HIV+, CD8 <sup>+</sup> T-cell categories compared to the HIV-uninfected group.....	44

## ACKNOWLEDGEMENTS

With a deep sense of gratitude, I would like to thank my thesis advisor, Dr. John W. Wilson, for his kind words and suggestions in the preparation and write-up of this work. Despite your schedule, you were always ready to give assistance and I thank you for this.

Much appreciation also goes to Dr. Chung-Chou (Joyce) Ho-Chang for helping me gain a much clearer understanding of the dataset and study design. Thank you so much for your extreme patience and explanations.

Words fail me in expressing my thanks to Dr. Matthew Freiberg. Your enthusiasm, mentorship and incisive comments have been invaluable in giving me a well-rounded picture of the statistical and clinical aspects of the research problem. Being a part of your research team has been a real educational experience and I thank you for the wonderful opportunity.

I would also like to thank Kaku Armah for his numerous critiques and proof-reading. I have gleaned much from your experience and I truly appreciate all your time and effort.

In addition, I wish to acknowledge the advice from Dr. Richard Day, who served as my thesis advisor until his retirement. Not to be minimized too are the efforts of all involved in the creation of the VACS-Virtual Cohort, without whom this study could not have been attempted.

Special thanks to Dr. Richard Hunt for his generous contributions on HIV natural history.

Finally, I thank my family for their love, prayers and encouragement throughout this process. Most of all, I thank Almighty God, Jehovah, for enabling this study to be a reality.


## 1.0 INTRODUCTION

### 1.1 BACKGROUND

It has been observed that HIV-infected persons are at a higher risk for the development of myocardial infarction (MI) and other cardiovascular diseases compared to HIV-uninfected persons [1-5]. In the natural history of Human Immunodeficiency Virus (HIV) infection, CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts follow a characteristic pattern (Figure 1) [6-8]. Within the first two weeks following HIV infection, there is a large drop in the CD4<sup>+</sup> T-cell count while the CD8<sup>+</sup> T-cell count rises, but these levels soon regain near-normalcy. In the ensuing period, a strong cytotoxic immune response then occurs to achieve viremic control – large numbers of HIV viral particles are produced yet destroyed each day [6, 9]. Since most of the viral particles come from recently infected CD4<sup>+</sup> T cells, the CD4<sup>+</sup> T-cell count gradually declines as these cells are destroyed both by the virus and the immune system in the course of the infection. Spontaneous apoptosis of uninfected CD4<sup>+</sup> and CD8<sup>+</sup> T cells also occurs [6]. CD8<sup>+</sup> T-cell levels, however, remain persistently elevated.

Immune activation, in of itself, does not appear to be solely responsible for the high CD8<sup>+</sup> T-cell count. Rather, it has been demonstrated to be possibly due to homeostatic mechanisms to maintain the circulating T-cell pool [10]. Studies suggest that eventually, the persistent immune activation (of CD4<sup>+</sup> and CD8<sup>+</sup> T cells) from viral particles that are released

from latent reservoirs of continuous HIV replication, such as lymph nodes, leads to exhaustion of quiescent naïve T cells available to replace them [11].



**Figure 1. Natural History of HIV**

Reproduced with permission:  
Richard Hunt [http://pathmicro.med.sc.edu/lecture/hiv\\_time\\_course2.jpg](http://pathmicro.med.sc.edu/lecture/hiv_time_course2.jpg)

Thus, at this stage CD8<sup>+</sup> T-cell levels drop dramatically, viremic control is lost and the individual becomes more prone to co-morbid disease, opportunistic infections and eventually AIDS. At late stages of HIV infection, mutant HIV virus particles are also able to directly infect CD8<sup>+</sup> T cells and destroy them, further contributing to the low CD8<sup>+</sup> T-cell count and immunodeficiency [6].

## 1.2 MOTIVATION FOR THE STUDY

Such findings have led to the question of whether a HIV-infected person's immune status could be indicative of the risk of MI [2]. Indeed, changes in the levels of CD4<sup>+</sup> and CD8<sup>+</sup> T cells have already been used as predictors for the progression to Acquired Immune Deficiency Syndrome (AIDS) [12-15]. It is also of interest whether a clinically-relevant measure of immune status could be demonstrated to consistently describe MI risk.

Previous studies have enumerated the usefulness of CD4<sup>+</sup> T-cell counts (and traditional risk factors such as hypertension, smoking, and diabetes, for example) in determining the risk of MI (or its surrogates) in HIV [2, 16, 17]. However, a MEDLINE®/PubMed® search of available literature revealed that as yet only one study had investigated the association between CD8<sup>+</sup> T-cell counts with MI risk in HIV [2]. The paucity of research into the predictive role of total CD8<sup>+</sup> T-cell counts associated with MI risk may be related to inconsistent results from studies attempting to associate these counts with HIV progression to AIDS: both significant [18, 19] and non-significant [20, 21] relationships have been reported. Some studies have demonstrated that immune activation may be associated with an increased risk of MI [16, 17], by focusing on biomarkers of immune activation and the CD4<sup>+</sup>/CD8<sup>+</sup> ratio [2]. These latter studies had some limitations in that they investigated surrogates of MI (e.g. subclinical carotid artery disease) and had relatively small sample sizes. Hence, the exact prognostic role of the CD8<sup>+</sup> T-cell count in this process has not been clearly shown.

### 1.3 PURPOSE OF THE STUDY

This study sought to investigate if any potential association exists between the total CD8<sup>+</sup> T-cell count and the risk of MI in a large cohort of HIV-infected and HIV-uninfected persons, adjusting for common traditional cardiovascular risk factors as well as HIV-specific parameters. Cases of fatal MI were also included in this study as they have sometimes been excluded in studies associating HIV with MI risk [22-24]. The implications of this research are of Public Health significance: Total CD8<sup>+</sup> T-cell counts are often obtained during routine care of HIV-infected persons but are usually used in the calculation of a CD4<sup>+</sup>/CD8<sup>+</sup> T-cell ratio [25]. This may not be wholly informative as the natural history of HIV (Figure 1) shows that the ratio could be very similar at different stages of disease. Hence, use of both total CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts in characterizing the immune status' association with MI risk could provide a measure that is of immediate relevance to clinical practice settings and could lead to an improvement in care of HIV-infected persons. The results of this study may also offer a better understanding of the immune system's role in the risk of MI in HIV-infected persons.

## **2.0 METHODS**

### **2.1 STUDY POPULATION**

A sample of 73,398 Veterans was derived from the U.S. Veterans Aging Cohort Study – Virtual Cohort (VACS-VC) [26, 27] for the study period between April 1, 2003 to December 31, 2009. This virtual cohort was created from VACS, an ongoing prospective, longitudinal cohort study group of HIV-infected Veterans matched (1:2) with HIV-uninfected Veterans based on demographic factors (including age and race) and Veterans Affairs Medical Center (VAMC) clinic site at which they were enrolled [27]. The VACS-VC has been in existence since 1998, utilizing a national electronic medical system from the U.S. Department of Veterans Affairs, such that matched Veterans are those enrolled in the same calendar year. The cohort comprises of data from at least five databases including the National Patient Care Database, the Immunology Case Registry, the Health Factor Dataset, the National Pharmacy Benefits Management Database, and the Decision Support System.

For better event ascertainment in this study, these data were combined with information from the Veterans-specific Ischemic Heart Disease Quality Enhancement Research Initiative (IHD-QUERI) database [28], and Medicare and Medicaid databases. Using the Veterans Health Administration’s Medical SAS® inpatient datasets [29] as well as the Veterans Affairs vital status electronic file, any MI-related deaths within the VACS-VC were identified. Information



from the Social Security Administration Death Master file and the Beneficiary Identification and Records Locator subsystem were also utilized in this identification process. The National Death Index was used to obtain information on the probable cause of death.

All participants provided written, informed consent. Institutional Review Board (IRB) approval for this study was obtained from the IRBs of the West Haven VAMC, Yale University and the University of Pittsburgh.

The selected sample from the VACS-VC consisted of 73,398 persons who were enrolled in VACS on or after April 1, 2003 and were free of pre-existing cardiovascular disease, including MI (based on clinical diagnosis and/ or International Classification of Diseases, 9th revision (ICD-9) codes). The baseline date was thus a participant's first clinic visit on or after April 1, 2003. Participants were then followed until the development of MI, death or the last observed follow-up date selected for this study (December 31, 2009).

## 2.2 DEPENDENT VARIABLE

This was incident MI, i.e. all new cases of *definite* or *probable* MI [30] in the VACS-VC for the follow-up period aforementioned. MI events that were completely managed in non-VA hospitals were identified using inpatient ICD-9 code 410 data in the Medicare database, as has been utilized previously [1]. MI associated with death was of two types, using criteria by Ives et al – mortality within thirty days of MI diagnosis was classified as *definite fatal MI*, while death certificates noting mortality to be primarily a result of MI resulted in another class termed *probable fatal MI* [30].

Adjudicated MI events were used to minimize ascertainment bias. Following the Universal Definition of Myocardial Infarction guidelines [31], proper adjudication for MI included the existence of serially raised cardiac enzymes, Troponin I (or Troponin T) and Creatine Kinase MB fraction (CK MB), deemed significant for MI based on the laboratory assay used. Equally utilized was the presence of characteristic electrocardiogram (EKG) findings, especially ST segment elevation of  $\geq 0.1\text{mV}$  in any two or more contiguous EKG leads (except  $V_2$  and  $V_3$  leads), with or without the presence of left bundle branch heart block – an interruption in the electrical conduction pathway of the heart muscle that makes the left ventricle contract slower than the right ventricle instead of synchronously. Adjudication of MI events that were managed solely in hospitals other than the VAMC without transfer to a VA facility required the use of Medicare inpatient ICD-9 code 410 data, as has been employed in a previous study [1]. Using the Compensation and Pension Records Interchange (CAPRI) information service access [32], MI diagnosis was sought from electronic medical records for VACS-VC participants, with due consideration of discharge summary documentation, laboratory test results and inpatient/outpatient ward and/or clinic reviews.

## **2.3 PREDICTOR VARIABLES**

### **2.3.1 Primary Independent Variable**

The main independent variable of interest was the total  $\text{CD8}^+$  T-cell count recorded at baseline. As  $\text{CD8}^+$  T-cell counts were available only for Veterans that were HIV-seropositive, study participants were classified as being either HIV-uninfected, or HIV-infected with  $\text{CD8}^+$  T-cell

tertiles of  $\leq 666$ , 667–1065 and  $\geq 1066$  cells/ mm<sup>3</sup> at baseline. In separate analyses, the total CD8<sup>+</sup> T-cell count variable was stratified by baseline CD4<sup>+</sup> T-cell level categories of clinical importance [33]. Baseline CD8<sup>+</sup> T-cell count was also assessed as a continuous variable for HIV-infected participants.

### **2.3.2 Covariates**

Data on demographic variables, traditional cardiovascular risk factors [34, 35] of high blood pressure, high lipid levels, obesity, diabetes, and smoking were obtained from medical records and ICD-9 codes. Other covariates identified were renal disease, substance abuse (cocaine and alcohol), Hepatitis C virus infection, anemia, and use of statins. Data on HIV viral load and antiretroviral therapy were also included for HIV-infected participants.

#### **2.3.2.1 Blood pressure**

Blood pressure measurement at baseline was the average of three routine outpatient observations closest to the date of enrollment. Using the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) definition for hypertension [36], participants were stratified as being either non-hypertensive (i.e. <140/90 mmHg and not on anti-hypertensive medication) or controlled-hypertensive (i.e. <140/90 mmHg and on anti-hypertensive medication) or uncontrolled-hypertensive (i.e.  $\geq 140/90$  mmHg).

#### **2.3.2.2 Lipid levels**

Lipid level measurements were of high density lipoprotein (HDL) cholesterol levels, low density lipoprotein (LDL) cholesterol levels and triglyceride (TG) levels and classified following the

National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) clinical guidelines [37]. LDL cholesterol levels were optimal (<100 mg/dL), above optimal (100-129 mg/dL), borderline high (130-159 mg/dL), and high to very high (160 mg/dL and above). HDL cholesterol levels were high (60 mg/dL and above), or low (< 40mg/dL), TG levels were optimal to normal (<150 mg/dL) or borderline high to high and very high – broadly grouped as being ‘elevated’ – (150 mg/dL and above).

### **2.3.2.3 Obesity**

Obesity was defined as a body mass index (BMI) of 30 kg/m<sup>2</sup> and above [38].

### **2.3.2.4 Renal Disease**

Renal disease was classified using clinical practice guidelines [39], based on estimated glomerular filtration rate (eGFR), as normal kidney function to mild chronic kidney disease ( $\geq 60$  mL/min/1.73m<sup>2</sup>), moderate chronic kidney disease (30-59 mL/min/1.73m<sup>2</sup>), or severe kidney disease to kidney failure (<30 mL/min/1.73m<sup>2</sup>).

### **2.3.2.5 Diabetes**

Diabetes was identified as being either present or absent in as per medical record documentation and ICD-9 codes using an algorithm that has been previously employed [1, 40, 41].

### **2.3.2.6 Smoking History**

Participants’ smoking history was classified as either ‘never smoked’, ‘previously smoked’ or ‘currently smoking’ [1].

### **2.3.2.7 Substance Abuse**

Cocaine and alcohol abuse were defined as being present or absent using ICD-9 codes [1, 42].

### **2.3.2.8 Hepatitis C Virus Infection**

Hepatitis C virus infection was deemed present if a laboratory diagnosis or ICD-9 codes for one or more inpatient records or two or more outpatient records identified this infection [1, 43].

### **2.3.2.9 Hemoglobin Concentration**

For persons older than 15 years, the World Health Organization [44] defines the threshold for anemia in males and in non-pregnant females as 13 g/dL and 12 g/dL respectively. Thus hemoglobin concentration was categorized in 0.1 unit decrements as  $\geq 14.0$  g/dL (normal), 12.0-13.9 g/dL, 10-11.9 g/dL and  $\leq 10$ g/dL (the concentration at which transfusion may begin to be indicated).

### **2.3.2.10 Covariates Specific to HIV-Infected Veterans**

For HIV-infected Veterans, HIV-1 RNA viral load and CD4<sup>+</sup> T cell count were also obtained at baseline. Antiretroviral therapy (ART) use was categorized as either: (1) none, (2) a combination of Nucleoside Reverse Transcriptase Inhibitors with a Non-Nucleoside Reverse Transcriptase inhibitor (NRTI + NNRTI), (3) a combination of NRTI with a Protease Inhibitor (PI), or (4) some other drug combination. It has been reported that most Veterans obtain ART within the VA system [27].

## 2.4 STATISTICAL METHODS AND ANALYSES

As the primary aim of the study was to investigate the prognostic value of CD8<sup>+</sup> T-cell levels in the setting of HIV, the study participants were first stratified by HIV status and then HIV-infected Veterans were further stratified by baseline CD8<sup>+</sup> T-cell counts (in tertiles). Based on this categorization, differences in the independent variables were compared. Pearson's Chi-squared tests of independence were used to assess categorical variables. The Pearson's Chi-squared test assumes that the observations are a simple random sample from the population where each participant had an equal probability of selection, assumes that the overall sample is 'large' (often greater than 30), assumes that expected 'table cell' counts are not less than five in 80% of the cells, and assumes that observations are independent of each other. Continuous variables were assessed using either Analysis of Variance (ANOVA) tests or the Kruskal-Wallis One way ANOVA test if necessary. ANOVA is a parametric test, meaning it is used for data that follow a normal or asymptotically-normal distribution, used to compare the equality of means of several different groups. The Kruskal-Wallis test is a non-parametric test, meaning it is used for data that do not have a normal or asymptotically-normal distribution assumption. However it does assume that the distributions of the variables have a similar shape and scale.

Using the following general formula:

$$\text{Incidence rate} = \frac{\text{Number of MI events}}{\text{Person-years for specific category}}$$

incidence rates of MI per 10,000 person-years of follow-up were calculated for each of the HIV-CD8<sup>+</sup> T-cell categories. Rates for mortality from any cause per 10,000 person years were also calculated. Additionally, the CD8<sup>+</sup> T-cell tertiles were stratified by baseline CD4<sup>+</sup> T-cell levels of clinical importance and rates were calculated for these new categories as well. Ninety-five per

cent confidence intervals for each of the rates were estimated using a quadratic approximation to the Poisson log likelihood for the log rate parameter [45].

## 2.5 REGRESSION MODELS

Cox proportional hazard regression models [46] were then used to determine the association between baseline CD8<sup>+</sup> T-cell counts and MI in terms of hazard ratios, 95% confidence intervals and *P* values, adjusting for all of the covariates. A proportional hazards model is a regression model used in time-to-event analyses whereby the intensity with which the event occurs (its hazard or risk) is multiplicatively proportional to some function of the hazard which all members in the cohort face (the baseline hazard rate,  $h_0(t)$ ).

Mathematically,

$$h(t|x_j) = h_0(t) \exp(x_j\beta_x)$$

and

$$\frac{h(t|x_j)}{h(t|x_m)} = \frac{\exp(x_j\beta_x)}{\exp(x_m\beta_x)}$$

where  $h(t|x_j)$  and  $h(t|x_m)$  are the hazard rates of the *j*th and *m*th persons in a dataset, with  $x_j$  and  $x_m$  as their respective covariates,  $\beta_x$  as the respective beta-coefficients of these covariates, and with the caveat that  $x_j$  and  $x_m$  are assumed to remain constant over time [47].

The baseline CD8<sup>+</sup> T-cell count was assessed in separate models as a categorical and continuous variable. Another proportional hazards model was also created in which the

categorical CD8<sup>+</sup> T-cell count was stratified by clinically-important CD4<sup>+</sup> T-cell count categories. A separate proportional hazards model for HIV-infected participants was also constructed to include the effects of HIV viral load, baseline CD4<sup>+</sup> T-cell measurements and antiretroviral therapy as covariates. Separate models with and without baseline CD4<sup>+</sup> T-cell measurements were compared to eliminate possible collinearity. Assumptions of proportional hazards were also checked using scaled Schoenfeld residuals tests. Kaplan-Meier survival estimates were calculated to describe survival time to MI for the CD8<sup>+</sup> T-cell categories.

Stata® software package, version 12, was used for all statistical analyses.

## 2.6 MISSING DATA

Proper statistical inference may be hindered in the presence of missing data, especially in large datasets [48]. Multiple imputation is a widely-accepted statistical technique for handling missing data and involves the replacement of a missing value by two or more imputed, plausible values, thereby creating simulated datasets containing each of these values [48]. The imputed datasets are analyzed separately by standard procedures and then their results are averaged. In this study, missing data was assumed to be missing at random and multiple imputation techniques were used to generate five datasets in order to handle the missing data for the covariates. The choice of five sets of imputations follows the recommendation by Rubin [48].



## 3.0 RESULTS

### 3.1 BASELINE CHARACTERISTICS

A total of 73,398 study participants were included in the study and followed for a total period of about 6.8 years. The majority was male with a median age of 48 years (mean  $\pm$  SD = 48.5  $\pm$  9.3, Table 1). Participants were categorized as being either HIV-uninfected, or HIV-infected within the lowest, intermediate or highest baseline CD8<sup>+</sup> T-cell tertile (i.e.  $\leq$ 666 cells/mm<sup>3</sup>, 667–1065 cells/mm<sup>3</sup> and  $\geq$ 1066 cells/mm<sup>3</sup> respectively). Despite prior matching at enrollment into the VACS, members of the sample from the virtual cohort still differed by HIV-CD8<sup>+</sup> T-cell tertile status for almost all covariates ( $P \leq$ 0.004 for substance abuse,  $P \leq$ 0.001 for others). No significant differences were seen in the use of Non-Nucleoside Reverse Transcriptase Inhibitor medication (NNRTI) among HIV-infected participants ( $P = 0.423$ ). Additionally, low HDL cholesterol and elevated Triglycerides were highest among HIV-infected participants in the highest CD8<sup>+</sup> tertile.

**Table 1. Baseline Characteristics of HIV-Infected and Matched HIV-Uninfected Veterans, Stratified by CD8<sup>+</sup> T-cell Level<sup>a</sup>**

Baseline Characteristics	HIV-uninfected (n = 55,109)	HIV-infected (n = 18,289)		
		CD8 <sup>+</sup> lowest tertile (≤666 cells/mm <sup>3</sup> ) (n = 5,987)	CD8 <sup>+</sup> intermediate tertile (667 – 1065 cells/mm <sup>3</sup> ) (n = 6,185)	CD8 <sup>+</sup> highest tertile (>1066 cells/mm <sup>3</sup> ) (n = 6,117)
Age (years), n (median ± IQR, mean ± SD)	55,109 (49.00 ± 11.00, 48.76 ± 9.24)	5,987 (48.00 ± 12.00, 48.02 ± 9.28)	6,185 (48.00 ± 13.00, 47.54 ± 9.37)	6,117 (48.00 ± 12.00, 47.90 ± 9.27)
Males (n, %)	53, 572 (97.21%)	5,813 (97.09%)	6,050 (97.82%)	5,988 (97.89%)
Race/ethnicity (n, %)				
African American	26,358 (47.83%)	2,999 (50.09%)	2,869 (46.39%)	2,887 (47.20%)
Hispanic	4,294 (7.79%)	524 (8.75%)	459 (7.42%)	423 (6.92%)
White	20,827 (37.79%)	2,077 (34.69%)	2,441 (39.47%)	2,434 (39.79%)
Other	3,630 (6.59%)	387 (6.46%)	416 (6.73%)	373 (6.10%)
<b>Traditional CHD risk factors</b>				
Blood pressure (BP) (n, %)				
Non-hypertensive	31,522 (58.41%)	4,098 (69.05%)	4,133 (67.38%)	4,035 (66.55%)
Controlled-hypertensive	5,210 (9.65%)	443 (7.46%)	432 (7.04%)	404 (6.66%)
Uncontrolled-hypertensive	17,236 (31.94%)	1,394 (23.49%)	1,569 (25.58%)	1,624 (26.79%)
Diabetes (n, %)	11,385 (20.66%)	724 (12.09%)	806 (13.03%)	954 (15.60%)
Lipid profile (n, %)				
Triglycerides ≥ 150 mg/dL	16,247 (38.24%)	2,186 (43.41%)	2,587 (47.89%)	2,918 (54.47%)
HDL cholesterol ≥ 60 mg/dL	5,980 (14.76%)	621 (13.90%)	504 (10.54%)	372 (7.91%)
HDL cholesterol 40 - 59 mg/dL	19,161 (47.28%)	1,692 (37.84%)	1,832 (38.33%)	1,682 (35.77%)
HDL cholesterol < 40 mg/dL	15,382 (37.96%)	2,157 (48.27%)	2,444 (51.13%)	2,648 (56.32%)
LDL cholesterol <100 mg/dL	12,223 (31.70%)	2,152 (50.80%)	2,071 (44.93%)	2,046 (44.87%)
LDL cholesterol 100-129 mg/dL	12,842 (33.30%)	1,155 (27.27%)	1,376 (29.84%)	1,391 (30.50%)
LDL cholesterol 130-159 mg/dL	8,783 (22.78%)	598 (14.12%)	762 (16.52%)	739 (16.21%)
LDL cholesterol ≥ 160 mg/dL	4,715 (12.23%)	331 (7.81%)	401 (8.72%)	384 (8.42%)
Body Mass Index ≥ 30kg/m <sup>2</sup> (n, %)	20,762 (38.78%)	632 (10.67%)	836 (13.63%)	1,006 (16.57%)
Smoking history (n, %)				
Never	15,235 (29.95%)	1,582 (28.19%)	1,615 (27.41%)	1,630 (28.12%)
Past	8,154 (16.03%)	744 (13.26%)	767 (13.02%)	803 (13.85%)
Current	27,487 (54.03%)	3,286 (58.55%)	3,509 (59.57%)	3,363 (58.02%)

(continued)

**Table 1 (continued)**

Baseline Characteristics	HIV-uninfected (n = 55,109)		HIV-infected (n = 18,289)	
		CD8 <sup>+</sup> lowest tertile (≤666 cells/mm <sup>3</sup> ) (n = 5,987)	CD8 <sup>+</sup> intermediate tertile (667 – 1065 cells/mm <sup>3</sup> ) (n = 6,185)	CD8 <sup>+</sup> highest tertile (>1066 cells/mm <sup>3</sup> ) (n = 6,117)
<b>Other risk factors</b>				
Hepatitis C virus infection (n, %)	8,591 (15.59%)	2,154 (35.98%)	2,062 (33.34%)	1,954 (31.94%)
Estimated Glomerular Filtration Rate (eGFR) (n, %)				
eGFR ≥ 60 mL/min/1.73m <sup>2</sup>	45,837 (95.19%)	5,321 (92.64%)	5,567 (94.12%)	5,490 (93.53%)
eGFR 30 - 59 mL/min/1.73m <sup>2</sup>	2,037 (4.23%)	318 (5.54%)	282 (4.77%)	313 (5.33%)
eGFR < 30 mL/min/1.73m <sup>2</sup>	281 (0.58%)	105 (1.83%)	66 (1.12%)	67 (1.14%)
Use of Statins (n, %)	5,393 (9.79%)	311 (5.19%)	433 (7.00%)	479 (7.83%)
Hemoglobin (Hb) (n, %)				
Hb ≥ 14.0 g/dL	33,788 (72.46%)	2,543 (46.41%)	3,436 (60.50%)	3,537 (62.09%)
Hb 12.0 – 13.9 g/dL	10,906 (23.39%)	1,894 (34.56%)	1,731 (30.48%)	1,702 (29.88%)
Hb 10.0 – 11.9 g/dL	1,554 (3.33%)	729 (13.30%)	406 (7.15%)	363 (6.37%)
Hb < 10.0 g/dL	383 (0.82%)	314 (5.73%)	106 (1.87%)	95 (1.67%)
<b>History of Substance Use</b>				
Cocaine abuse or dependence	3,968 (7.20%)	705 (11.78%)	654 (10.57%)	586 (9.58%)
Alcohol abuse or dependence	7,265 (13.18%)	851 (14.21%)	792 (12.81%)	736 (12.03%)
<b>Baseline Laboratory Analysis</b>				
CD4 <sup>+</sup> T-cell level				
≥500 cells/ mm <sup>3</sup>	...	1,097 (20.36%)	1,971 (35.27%)	2,354 (41.86%)
200 – 499 cells/ mm <sup>3</sup>	...	1,901 (35.29%)	2,447 (43.78%)	2,382 (42.36%)
<200 cells/ mm <sup>3</sup>	...	2,389 (44.35%)	1,171 (20.95%)	887 (15.77%)
HIV-1 RNA copies/ mL				
<500 copies/ mL	...	2,388 (43.66%)	2,680 (47.33%)	2,428 (42.52%)
≥500 copies/ mL	...	3,081 (56.34%)	2,982 (52.67%)	3,282 (57.48%)
<b>Antiretroviral therapy use</b>				
(n, %)				
None	...	2,901 (48.46%)	2,827 (45.71%)	2,645 (43.24%)
NRTI + NNRTI	...	1,437 (24.00%)	1,523 (24.62%)	1,446 (23.64%)
NRTI + PI	...	1,219 (20.36%)	1,393 (22.52%)	1,547 (25.29%)
Other combination	...	430 (7.18%)	442 (7.15%)	479 (7.83%)

<sup>a</sup> The variables with missing data were blood pressure, HDL level, LDL level, TG level, Smoking history, eGFR category, Body Mass Index ≥30kg/m<sup>2</sup>, Hemoglobin concentration, baseline CD4<sup>+</sup> count and baseline viral load. Please see Appendix for details.

Abbreviations used: SD, standard deviation; IQR, interquartile range; CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; HIV, Human Immunodeficiency Virus; RNA, Ribonucleic Acid; NRTI, Nucleoside Reverse Transcriptase Inhibitor, NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor; PI, Protease Inhibitor.

### 3.2 RATES OF MI

There were 766 cases of MI observed during the entire follow-up period, giving a rate of 18.49 per 10,000 person years (95% CI: 16.95 to 20.17) among HIV-uninfected Veterans and 28.52 per 10,000 person years (95% CI: 25.24 to 32.22) among HIV-infected Veterans. As shown in Tables 2 and 3, the rates of MI were consistently higher among HIV-infected Veterans, regardless of the CD8<sup>+</sup> T-cell count stratification, compared to HIV-uninfected Veterans. The highest rate of MI was seen in the HIV-infected group within the CD8<sup>+</sup> T-cell category  $\geq 1066$  cells/mm<sup>3</sup> with a rate of 32.20 per 10,000 person years (95% CI: 26.50 to 39.14), when participants were stratified based on only their HIV status and CD8<sup>+</sup> T-cell count (Table 2). MI rates were also compared with all-cause mortality rates for each category (Tables 2 and 3).

**Table 2. MI Rates compared with Mortality Rates, by Baseline CD8<sup>+</sup> T-cell Level (per 10,000 person years)**

	No. of MI Events	MI Rate <sup>a</sup> (95% CI)	No. of Deaths	Mortality Rate
HIV-uninfected	508	18.49 (16.95 – 20.17)	4,674	18.63 (18.10 – 19.17)
HIV-infected				
CD8 <sup>+</sup> $\leq 666$ cells/mm <sup>3</sup>	72	26.08 (20.70 – 32.86)	1,449	63.17 (60.00 – 66.51)
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	85	26.98 (21.81 – 33.37)	1,005	38.54 (36.23 – 41.00)
CD8 <sup>+</sup> $\geq 1066$ cells/mm <sup>3</sup>	101	32.20 (26.50 – 39.14)	1,045	40.89 (38.49 – 43.45)

<sup>a</sup> 1 missing record (0.0014% of the total)

Abbreviations used: HIV, Human Immunodeficiency Virus; MI, Myocardial infarction

When participants were stratified based on their HIV status and CD8<sup>+</sup> T-cell count in the context of their baseline CD4<sup>+</sup> T-cell count using clinical cut-points (Table 3, Figure 2), the rates of MI were again consistently higher among HIV-infected Veterans.

The highest MI rates were seen in the following instances:

- 1) within the highest tertile of CD8<sup>+</sup> T cells (for the CD4<sup>+</sup> T cells  $\geq 500$  cells/mm<sup>3</sup> category) with MI rate of 28.68 per 10,000 person years (95% CI: 20.96 to 39.26). This tertile also had the highest mortality rate within this CD4<sup>+</sup> T-cell category.
- 2) within the highest tertile of CD8<sup>+</sup> T cells (for the CD4<sup>+</sup> T cells 200–499 cells/mm<sup>3</sup> category) with MI rate of 37.38 per 10,000 person years (95% CI: 28.25 to 49.46). The mortality rate

**Table 3. MI Rates compared with Mortality Rates by Baseline CD4<sup>+</sup>T-cell Clinical Cut-points and Baseline CD8<sup>+</sup> T-cell Level (per 10,000 person years)**

	No. of MI Events	MI Rate <sup>a</sup>	No. of Deaths	Mortality Rate
HIV-uninfected	508	18.49 (16.95 – 20.17)	4,674	18.63 (18.10 – 19.17)
HIV-infected				
<b>CD4<sup>+</sup> <math>\geq 500</math> cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> $\leq 666$ cells/mm <sup>3</sup>	16	24.00 (14.70 – 39.18)	160	28.08 (24.05 – 32.78)
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	31	26.68 (18.76 – 37.93)	242	24.83 (21.89 – 28.17)
CD8 <sup>+</sup> $\geq 1066$ cells/mm <sup>3</sup>	39	28.68 (20.96 – 39.26)	340	30.66 (27.57 – 34.10)
<b>CD4<sup>+</sup> 200-499 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> $\leq 666$ cells/mm <sup>3</sup>	23	21.54 (14.32 – 32.42)	464	43.88 (39.72 – 48.48)
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	36	26.08 (18.81 – 36.16)	428	37.68 (34.27 – 41.42)
CD8 <sup>+</sup> $\geq 1066$ cells/mm <sup>3</sup>	49	37.38 (28.25 – 49.46)	387	43.52 (39.74 – 47.67)
<b>CD4<sup>+</sup> <math>&lt; 200</math> cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> $\leq 666$ cells/mm <sup>3</sup>	33	32.16 (22.86 – 45.23)	902	107.13 (100.36 – 114.35)
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	18	29.60 (18.65 – 46.97)	335	67.40 (60.56 – 75.02)
CD8 <sup>+</sup> $\geq 1066$ cells/mm <sup>3</sup>	13	27.89 (16.19 – 48.02)	241	63.32 (55.81 – 71.85)


<sup>a</sup> 1 missing record (0.0014% of the total)

Abbreviations used: HIV, Human Immunodeficiency Virus; MI, Myocardial infarction

for this tertile was 0.36 per 10,000 person years below the highest mortality rate within this CD4<sup>+</sup> T-cell category; and

3) within the lowest tertile of CD8<sup>+</sup> T cells (for the CD4<sup>+</sup> T cells < 200 cells/mm<sup>3</sup> category), with MI rate of 32.16 per 10,000 person years (95% CI: 22.86 – 45.23). The mortality rate was highest in this tertile for this CD4<sup>+</sup> T-cell category.

The MI rates among HIV-infected participants were observed to have overlapping 95% confidence intervals. All-cause mortality appeared to rise with decreasing CD4<sup>+</sup> T-cell levels.




**Figure 2. Rates of MI and Rates of All-cause mortality by T-cell count**

### 3.3 ESTIMATES OF SURVIVAL FUNCTION

Kaplan-Meier estimates of survival time to MI were graphed to show the survival distribution of the different CD8<sup>+</sup> T-cell categories (see Appendix for Risk tables). When Veterans were stratified by HIV-CD8<sup>+</sup> T-cell status alone (Figure 3), the estimated survival functions for the

lowest and highest CD8<sup>+</sup> tertile ( $\leq 666$  and  $>1065$  cells/mm<sup>3</sup> respectively) were seen to be very similar to each other. In contrast, the curve for the middle CD8<sup>+</sup> tertile (666-1065 cells/mm<sup>3</sup>) was similar to the HIV-uninfected participants for the most part until after about four years of follow-up time. Median survival time was not observed in any of the categories, indicating the rarity of MI events in this cohort.




**Figure 3. Graph of Kaplan-Meier survival estimates of MI development for different HIV/CD8<sup>+</sup> T-cell strata**

Abbreviations used: HIV- , HIV-uninfected; HIV+, HIV-infected.

When Veterans were stratified by both CD8<sup>+</sup> T-cell and CD4<sup>+</sup> T-cell levels according to HIV status (Figure 4), the Kaplan-Meier curves were less distinct due to the number of groups. However, formal tests of the equality of survival functions revealed that the survival experiences of different CD8<sup>+</sup> categories within each CD4<sup>+</sup> T-cell level were not statistically different from

one another (see Appendix). One category among the HIV-infected Veterans seemingly had a ‘better’ initial survival experience than the HIV-uninfected group (Figure 4). Subsequent investigation revealed this to be as a result of the relatively fewer number of participants in this category early in the follow-up period – hence fewer MI events were recorded during that period.



**Figure 4. Graph of Kaplan-Meier survival estimates of MI development for different HIV/CD8<sup>+</sup> T-cell strata by CD4<sup>+</sup> T-cell level**

Abbreviations used: HIV- , HIV-uninfected; HIV+, HIV-infected.

### 3.4 ESTIMATED MI RISK

Proportional hazard models showed that MI risk was greatest among HIV-infected participants in the highest CD8<sup>+</sup> T-cell tertile compared with HIV-uninfected participants (Table 4), following adjustment for all covariates (Hazard ratio, HR= 1.82, 95% CI: 1.46 to 2.28, *P* <0.001).



With additional stratification by CD4<sup>+</sup> T-cell clinical cut-points (Table 4), MI risk was greatest among those within the highest CD8<sup>+</sup> T-cell tertile who were also in the CD4<sup>+</sup> T-cell category of either  $\geq 500$  cells/mm<sup>3</sup> (adjusted HR = 1.69, 95% CI: 1.21 to 2.36,  $P = 0.002$ ) or 200–499 cells/mm<sup>3</sup> (adjusted HR = 2.08, 95% CI: 1.53 to 2.82,  $P < 0.001$ ). Persons who were in the CD4<sup>+</sup> T-cell category of  $< 200$  cells/mm<sup>3</sup> were at greatest risk for MI if they were correspondingly within the lowest CD8<sup>+</sup> T-cell tertile (adjusted HR = 1.82, 95% CI: 1.26 to 2.64,  $P = 0.001$ ).

**Table 4. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8<sup>+</sup> T-cell levels and MI**

Covariates	HR (95% CI) <sup>a</sup>	P value	HR (95% CI) <sup>b</sup>	P value
<b><u>HIV status</u></b>				
HIV-uninfected	1.00 (reference)		1.00 (reference)	
<b><u>HIV infected by CD8<sup>+</sup> count</u></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	1.45 (1.12 – 1.88)	0.005	...	...
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	1.54 (1.21 – 1.96)	<0.001	...	...
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	1.82 (1.46 – 2.28)	<0.001	...	...
<b><u>HIV infected by CD4<sup>+</sup> &amp; CD8<sup>+</sup> count</u></b>				
<b>CD4<sup>+</sup> ≥ 500 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	...	...	1.30 (0.76 – 2.20)	0.339
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	...	...	1.51 (1.03 – 2.21)	0.037
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	...	...	1.69 (1.21 – 2.36)	0.002
<b>CD4<sup>+</sup> 200-499 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	...	...	1.22 (0.80 – 1.87)	0.360
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	...	...	1.47 (1.03 – 2.09)	0.034
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	...	...	2.08 (1.53 – 2.82)	<0.001
<b>CD4<sup>+</sup> &lt; 200 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	...	...	1.82 (1.26 – 2.64)	0.001
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	...	...	1.80 (1.10 – 2.94)	0.019
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	...	...	1.51 (0.85 – 2.67)	0.158
Age (in 10-year increments)	1.80 (1.66 – 1.96)	<0.001	1.81 (1.66 – 1.96)	<0.001
Female	0.34 (0.14 – 0.82)	0.017	0.34 (0.14 – 0.82)	0.017
<b>Race/ethnicity</b>				
African American	0.74 (0.63 – 0.87)	<0.001	0.74 (0.63 – 0.87)	<0.001
Hispanic	1.07 (0.83 – 1.38)	0.602	1.07 (0.83 – 1.38)	0.593
White	1.00 (reference)		1.00 (reference)	
Other	0.59 (0.39 – 0.88)	0.009	0.59 (0.39 – 0.87)	0.009
<b><u>Traditional CHD risk factors</u></b>				
<b>Blood pressure (BP)</b>				
Non-hypertensive	1.00 (reference)		1.00 (reference)	
Controlled-hypertensive	1.36 (1.07 – 1.72)	0.013	1.36 (1.07 – 1.72)	0.013
Uncontrolled-hypertensive	1.66 (1.42 – 1.95)	<0.001	1.67 (1.42 – 1.96)	<0.001
Diabetes	1.74 (1.48 – 2.04)	<0.001	1.74 (1.48 – 2.04)	<0.001

(continued)

**Table 4. (continued)**

Covariates	HR (95% CI) <sup>a</sup>	P value	HR (95% CI) <sup>b</sup>	P value
<b>Lipid profile</b>				
Triglycerides ≥ 150 mg/dl	1.17 (0.99 – 1.37)	0.058	1.17 (0.99 – 1.37)	0.059
HDL cholesterol ≥ 60 mg/dl	1.00 (reference)		1.00 (reference)	
HDL cholesterol 40 - 59 mg/dl	1.02 (0.79 – 1.33)	0.862	1.02 (0.79 – 1.33)	0.860
HDL cholesterol < 40 mg/dl	1.05 (0.81 – 1.36)	0.724	1.04 (0.80 – 1.36)	0.743
LDL cholesterol <100 mg/dl	1.00 (reference)		1.00 (reference)	
LDL cholesterol 100-129 mg/dl	1.15 (0.95 – 1.38)	0.145	1.15 (0.96 – 1.38)	0.139
LDL cholesterol 130-159 mg/dl	1.54 (1.23 – 1.93)	<0.001	1.55 (1.24 – 1.94)	<0.001
LDL cholesterol ≥ 160 mg/dl	1.71 (1.33 – 2.21)	<0.001	1.72 (1.34 – 2.22)	<0.001
Body Mass Index ≥ 30kg/m <sup>2</sup>	0.99 (0.83 – 1.17)	0.895	0.99 (0.84 – 1.17)	0.914
<b>Smoking history</b>				
Never	1.00 (reference)		1.00 (reference)	
Past	1.07 (0.82 – 1.40)	0.591	1.08 (0.83 – 1.40)	0.575
Current	1.73 (1.43 – 2.09)	<0.001	1.72 (1.42 – 2.09)	<0.001
<b>Other risk factors</b>				
Hepatitis C virus infection	1.17 (0.98 – 1.40)	0.087	1.17 (0.98 – 1.40)	0.082
<b>Estimated Glomerular Filtration Rate (eGFR)</b>				
eGFR ≥ 60 ml/min/1.73m <sup>2</sup>	1.00 (reference)		1.00 (reference)	
eGFR 30 - 59 ml/min/1.73m <sup>2</sup>	1.50 (1.16 – 1.95)	0.002	1.50 (1.16 – 1.95)	0.003
eGFR < 30 ml/min/1.73m <sup>2</sup>	3.23 (2.14 – 4.86)	<0.001	3.28 (2.17 – 4.95)	<0.001
Use of Statins	0.85 (0.68 – 1.06)	0.147	0.85 (0.68 – 1.06)	0.149
<b>Hemoglobin (Hb)</b>				
Hb ≥ 14.0 mg/dl	1.00 (reference)		1.00 (reference)	
Hb 12.0 – 13.9 mg/dl	1.23 (1.03 – 1.47)	0.024	1.22 (1.02 – 1.47)	0.028
Hb 10.0 – 11.9 mg/dl	2.13 (1.61 – 2.81)	<0.001	2.09 (1.58 – 2.77)	<0.001
Hb < 10.0 mg/dl	2.13 (1.29 – 3.52)	0.003	2.03 (1.22 – 3.38)	0.007
<b>History of Substance Use</b>				
Cocaine abuse or dependence	1.01 (0.74 – 1.38)	0.969	1.00 (0.73 – 1.37)	0.984
Alcohol abuse or dependence	1.11 (0.87 – 1.41)	0.403	1.11 (0.87 – 1.41)	0.405

<sup>a</sup> Model when CD8<sup>+</sup> T-cell level was not stratified by CD4<sup>+</sup> T-cell clinical cut-point

<sup>b</sup> Model when CD8<sup>+</sup> T-cell level was stratified by CD4<sup>+</sup> T-cell clinical cut-point

Abbreviations used: CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; HIV, Human Immunodeficiency Virus.

As the median age of members of the cohort was approximately 50 years (middle age) in all HIV-CD8<sup>+</sup> T-cell categories, proportional hazard models restricted to those either above or below this age were analyzed (Table 5), to examine if there was an age effect affecting the previous results. A median of 50 years indicated that approximately half of the study participants fell either above or below this age. Effects of CD8<sup>+</sup> T-cell counts lost statistical significance for most participant categories (likely due to reduced power). However, a consistent pattern of increasing MI risk with increasing CD8<sup>+</sup> T-cell levels was observed across all CD4<sup>+</sup> T-cell categories among those aged 50 years and above. The same pattern was seen in those below 50 years with the exception of the CD4<sup>+</sup> T-cell <200 cells/mm<sup>3</sup> category.

**Table 5. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8<sup>+</sup> T-cell levels and MI for persons below or above middle age (50 years)**

Covariates	HR (95% CI) <sup>a</sup>	P value	HR (95% CI) <sup>b</sup>	P value
<b><u>HIV status</u></b>				
HIV-uninfected	1.00 (reference)		1.00 (reference)	
<b><u>HIV infected by CD4<sup>+</sup> &amp; CD8<sup>+</sup> count</u></b>				
<b>CD4<sup>+</sup> ≥ 500 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	0.87 (0.27 – 2.86)	0.818	1.55 (0.84 – 2.89)	0.163
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	1.14 (0.56 – 2.34)	0.718	1.72 (1.09 – 2.71)	0.019
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	1.52 (0.86 – 2.71)	0.147	1.77 (1.16 – 2.67)	0.007
<b>CD4<sup>+</sup> 200-499 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	1.26 (0.58 – 2.72)	0.554	1.20 (0.71 – 2.04)	0.495
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	1.29 (0.69 – 2.41)	0.426	1.57 (1.02 – 2.41)	0.041
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	1.51 (0.82 – 2.75)	0.183	2.34 (1.63 – 3.34)	<0.001
<b>CD4<sup>+</sup> &lt; 200 cells/mm<sup>3</sup></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	1.93 (1.08 – 3.45)	0.027	1.63 (1.00 – 2.66)	0.052
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	2.01 (0.96 – 4.18)	0.062	1.65 (0.85 – 3.19)	0.136
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	0.64 (0.16 – 2.62)	0.540	1.87 (1.00 – 3.52)	0.050
Female	0.19 (0.05 – 0.79)	0.022	0.49 (0.16 – 1.53)	0.221
<b>Race/ethnicity</b>				
African American	0.75 (0.57 – 0.99)	0.044	0.71 (0.58 – 0.86)	0.003
Hispanic	1.03 (0.66 – 1.63)	0.887	1.08 (0.80 – 1.47)	0.605
White	1.00 (reference)		1.00 (reference)	
Other	0.39 (0.16 – 0.96)	0.041	0.67 (0.43 – 1.06)	0.086
<b><u>Traditional CHD risk factors</u></b>				
<b>Blood pressure (BP)</b>				
Non-hypertensive	1.00 (reference)		1.00 (reference)	
Controlled-hypertensive	1.94 (1.24 – 3.03)	0.003	1.40 (1.05 – 1.86)	0.020
Uncontrolled-hypertensive	1.81 (1.38 – 2.38)	<0.001	1.78 (1.46 – 2.17)	<0.001
Diabetes	2.04 (1.53 – 2.72)	<0.001	1.70 (1.40 – 2.06)	<0.001
<b>Lipid profile</b>				
Triglycerides ≥ 150 mg/dl	1.30 (0.96 – 1.75)	0.088	1.04 (0.85 – 1.26)	0.718
HDL cholesterol ≥ 60 mg/dl	1.00 (reference)		1.00 (reference)	
HDL cholesterol 40 - 59 mg/dl	0.86 (0.56 – 1.33)	0.499	1.12 (0.76 – 1.66)	0.542
HDL cholesterol < 40 mg/dl	0.88 (0.55 – 1.41)	0.596	1.13 (0.80 – 1.58)	0.486
LDL cholesterol <100 mg/dl	1.00 (reference)		1.00 (reference)	
LDL cholesterol 100-129 mg/dl	1.35 (0.94 – 1.96)	0.105	1.07 (0.85 – 1.35)	0.557
LDL cholesterol 130-159 mg/dl	1.94 (1.37 – 2.75)	<0.001	1.35 (0.99 – 1.85)	0.060
LDL cholesterol ≥ 160 mg/dl	2.11 (1.31 – 3.39)	0.003	1.46 (1.06 – 2.01)	0.020

(continued)

**Table 5. (continued)**

<b>Covariates</b>	<b>HR (95% CI)<sup>a</sup></b>	<b>P value</b>	<b>HR (95% CI)<sup>b</sup></b>	<b>P value</b>
Body Mass Index $\geq 30\text{kg/m}^2$	1.16 (0.87 – 1.54)	0.312	0.79 (0.64 – 0.98)	0.029
Smoking history				
Never	1.00 (reference)		1.00 (reference)	
Past	2.12 (1.44 – 3.11)	<0.001	1.40 (1.12 – 1.74)	0.003
Current	1.44 (0.84 – 2.46)	0.187	1.04 (0.79 – 1.38)	0.774
<b>Other risk factors</b>				
Hepatitis C virus infection	1.58 (1.19 – 2.11)	0.002	0.90 (0.72 – 1.13)	0.369
Estimated Glomerular Filtration Rate (eGFR)				
eGFR $\geq 60$ ml/min/1.73m <sup>2</sup>	1.00 (reference)		1.00 (reference)	
eGFR 30 - 59 ml/min/1.73m <sup>2</sup>	1.55 (0.87 – 2.77)	0.134	1.83 (1.38 – 2.43)	<0.001
eGFR < 30 ml/min/1.73m <sup>2</sup>	0.78 (0.19 – 3.24)	0.730	4.20 (2.71 – 6.51)	<0.001
Use of Statins	0.76 (0.48 – 1.21)	0.246	0.90 (0.70 – 1.15)	0.400
Hemoglobin (Hb)				
Hb $\geq 14.0$ mg/dl	1.00 (reference)		1.00 (reference)	
Hb 12.0 – 13.9 mg/dl	1.24 (0.90 – 1.72)	0.189	1.32 (1.07 – 1.63)	0.010
Hb 10.0 – 11.9 mg/dl	2.38 (1.42 – 4.02)	0.001	2.23 (1.61 – 3.10)	<0.001
Hb < 10.0 mg/dl	2.36 (0.94 – 5.95)	0.068	2.17 (1.18 – 4.00)	0.012
<b>History of Substance Use</b>				
Cocaine abuse or dependence	1.15 (0.73 – 1.81)	0.536	0.81 (0.52 – 1.28)	0.370
Alcohol abuse or dependence	1.00 (0.67 – 1.48)	0.995	1.07 (0.79 – 1.45)	0.674

<sup>a</sup> Model restricted to persons below 50 years old

<sup>b</sup> Model restricted to persons 50 years old and above

Abbreviations used: CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; HIV, Human Immunodeficiency Virus.

Additionally, a proportional hazards model specific to HIV-infected Veterans (Table 6) revealed that MI risk was greatest among those within the highest and middle CD8<sup>+</sup> T-cell tertiles compared to the lowest CD8<sup>+</sup> T-cell tertile following adjustments for viral load and antiretroviral therapy, but this was not statistically significant (adjusted HR = 1.25 and 1.07 respectively, *P* = 0.164 and 0.690 respectively, Table 6). A proportional hazards model with CD8<sup>+</sup> T-cell count as a continuous variable, for HIV- infected Veterans only (Table 6), revealed that the MI risk increased by 0.03% for every additional cell/mm<sup>3</sup> of CD8<sup>+</sup> T-cell count (*P*=0.004). The exclusion of the baseline CD4<sup>+</sup> T-cells variable from these two proportional hazard models just described did not reveal any marked changes in hazard ratios or standard errors (analyses not shown).

**Table 6. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8<sup>+</sup> T-cell levels and MI in HIV-Infected Veterans only**

Covariates	HR (95% CI) <sup>a</sup>	P value	HR (95% CI) <sup>b</sup>	P value
<b><u>HIV infected by CD8<sup>+</sup> count strata</u></b>				
CD8 <sup>+</sup> ≤ 666 cells/mm <sup>3</sup>	1.00 (reference)		...	...
CD8 <sup>+</sup> 667 – 1065 cells/mm <sup>3</sup>	1.07 (0.77 – 1.47)	0.690	...	...
CD8 <sup>+</sup> ≥ 1066 cells/mm <sup>3</sup>	1.25 (0.91 – 1.72)	0.164	...	...
<b><u>HIV infected with CD8<sup>+</sup> count as continuous variable</u></b>				
	...	...	1.0003 (1.0001 – 1.0005)	0.004
Age (in 10-year increments)	1.74 (1.50 – 2.01)	<0.001	1.74 (1.50 – 2.01)	<0.001
Female	0.41 (0.10 – 1.68)	0.217	0.42 (0.10 – 1.71)	0.224
Race/ethnicity				
African American	0.70 (0.52 – 0.93)	0.014	0.69 (0.52 – 0.92)	0.013
Hispanic	0.92 (0.59 – 1.45)	0.727	0.93 (0.59 – 1.47)	0.756
White	1.00 (reference)		1.00 (reference)	
Other	0.63 (0.32 – 1.24)	0.182	0.63 (0.32 – 1.24)	0.181
<b><u>Traditional CHD risk factors</u></b>				
Blood pressure (BP)				
Non-hypertensive	1.00 (reference)		1.00 (reference)	
Controlled-hypertensive	1.72 (1.13 – 2.61)	0.011	1.73 (1.13 – 2.63)	0.011
Uncontrolled-hypertensive	1.96 (1.49 – 2.58)	<0.001	1.96 (1.49 – 2.58)	<0.001
Diabetes	1.54 (1.15 – 2.06)	0.004	1.53 (1.15 – 2.05)	0.004
Lipid profile				
Triglycerides ≥ 150 mg/dl	1.36 (1.03 – 1.81)	0.030	1.36 (1.02 – 1.80)	0.034
HDL cholesterol ≥ 60 mg/dl	1.00 (reference)		1.00 (reference)	
HDL cholesterol 40 - 59 mg/dl	1.08 (0.64 – 1.83)	0.773	1.08 (0.63 – 1.82)	0.785
HDL cholesterol < 40 mg/dl	1.04 (0.60 – 1.81)	0.889	1.02 (0.59 – 1.78)	0.931
LDL cholesterol <100 mg/dl	1.00 (reference)		1.00 (reference)	
LDL cholesterol 100-129 mg/dl	1.02 (0.73 – 1.44)	0.902	1.02 (0.72 – 1.44)	0.907
LDL cholesterol 130-159 mg/dl	1.69 (1.17 – 2.43)	0.005	1.68 (1.17 – 2.42)	0.005
LDL cholesterol ≥ 160 mg/dl	1.26 (0.74 – 2.15)	0.388	1.26 (0.74 – 2.14)	0.398

(continued)



**Table 6. (continued)**

<b>Covariates</b>	<b>HR (95% CI)<sup>a</sup></b>	<b>P value</b>	<b>HR (95% CI)<sup>b</sup></b>	<b>P value</b>
Body Mass Index $\geq 30\text{kg/m}^2$	1.18 (0.84 – 1.66)	0.344	1.17 (0.83 – 1.64)	0.373
Smoking history				
Never	1.00 (reference)		1.00 (reference)	
Past	1.12 (0.75 – 1.67)	0.580	1.13 (0.76 – 1.68)	0.557
Current	1.47 (1.07 – 2.04)	0.019	1.48 (1.07 – 2.04)	0.018
<b>Other risk factors</b>				
Hepatitis C virus infection	1.29 (0.98 – 1.69)	0.065	1.30 (0.97 – 1.70)	0.062
Estimated Glomerular Filtration Rate (eGFR)				
eGFR $\geq 60$ ml/min/1.73m <sup>2</sup>	1.00 (reference)		1.00 (reference)	
eGFR 30 - 59 ml/min/1.73m <sup>2</sup>	1.44 (0.96 – 2.17)	0.081	1.43 (0.95 – 2.16)	0.086
eGFR $< 30$ ml/min/1.73m <sup>2</sup>	3.29 (1.25 – 4.57)	0.008	2.42 (1.27 – 4.62)	0.007
Use of Statins	1.03 (0.69 – 1.54)	0.876	1.04 (0.70 – 1.55)	0.856
Hemoglobin (Hb)				
Hb $\geq 14.0$ mg/dl	1.00 (reference)		1.00 (reference)	
Hb 12.0 – 13.9 mg/dl	1.29 (0.95 – 1.75)	0.107	1.29 (0.95 – 1.76)	0.103
Hb 10.0 – 11.9 mg/dl	2.06 (1.35 – 3.16)	0.001	2.09 (1.36 – 3.20)	0.001
Hb $< 10.0$ mg/dl	1.57 (0.71 – 3.49)	0.264	1.62 (0.73 – 3.59)	0.236
<b>Hx of Substance Use</b>				
Cocaine abuse or dependence	0.97 (0.59 – 1.59)	0.900	0.98 (0.60 – 1.60)	0.938
Alcohol abuse or dependence	1.15 (0.76 – 1.76)	0.504	1.15 (0.75 – 1.75)	0.526
<b>Baseline Laboratory Analysis</b>				
CD4 <sup>+</sup> T-cell level				
$\geq 500$ cells/ mm <sup>3</sup>	1.00 (reference)		1.00 (reference)	
200 – 499 cells/ mm <sup>3</sup>	1.06 (0.78 – 1.44)	0.706	1.08 (0.80 – 1.46)	0.621
$< 200$ cells/ mm <sup>3</sup>	1.22 (0.84 – 1.77)	0.302	1.27 (0.88 – 1.85)	0.200
HIV-1 RNA copies/ mL				
$< 500$ copies/ mL	1.00 (reference)		1.00 (reference)	
$\geq 500$ copies/ mL	1.10 (0.82 – 1.48)	0.539	1.08 (0.80 – 1.45)	0.620
<b>Antiretroviral therapy use</b>				
None	1.00 (reference)		1.00 (reference)	
NRTI + NNRTI	0.87 (0.62 – 1.22)	0.428	0.88 (0.63 – 1.24)	0.465
NRTI + PI	1.01 (0.63 – 1.62)	0.962	1.02 (0.63 – 1.63)	0.942
Other combination	0.99 (0.71 – 1.39)	0.974	1.00 (0.72 – 1.40)	0.989

<sup>a</sup> Model when CD8<sup>+</sup> T-cell level is treated as a categorical variable

<sup>b</sup> Model when CD8<sup>+</sup> T-cell level is treated as a continuous variable

Abbreviations used: CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; HIV, Human Immunodeficiency Virus; RNA, Ribonucleic Acid; NRTI, Nucleoside Reverse Transcriptase Inhibitor, NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor; PI, Protease Inhibitor.

The assumption of proportional hazards was not violated when participants were stratified by HIV status and CD8<sup>+</sup> T-cell level only (see Appendix). However when the HIV-infected participants were further stratified by CD4<sup>+</sup> T-cell level, the proportional hazards assumption was not met for the middle and low CD8<sup>+</sup> T-cell tertiles within the CD4<sup>+</sup>  $\geq 500$  cells/mm<sup>3</sup> category (i.e. 667-1065 and  $\leq 666$  cells/mm<sup>3</sup> groups).

## 4.0 DISCUSSION

This study examined whether an association exists between baseline total CD8<sup>+</sup> T-cell count and the risk of MI, in the setting of HIV, in a large, representative cohort. It is of Public Health importance in that the study findings may help improve the current management of HIV-infected persons, especially with regards to their MI risk.

In the sample of VACS-VC participants assessed, high CD8<sup>+</sup> T-cell counts ( $\geq 1066$  cells/mm<sup>3</sup>) were associated with the greatest risk of MI. This was demonstrated in regression models that considered both HIV-infected and HIV-uninfected participants and in secondary analysis restricted to HIV-infected participants. These results are in agreement with an earlier study by Lang et al which showed that, as an independent predictor, high CD8<sup>+</sup> T-cell counts are associated with an increased risk for MI [2]. They also agree with studies that looked at surrogates for MI (subclinical carotid artery disease), which showed that the risk was increased in the presence of markers for immune activation, including a low CD4<sup>+</sup>/CD8<sup>+</sup> T-cell ratio [16, 17]. However, CD4<sup>+</sup>/CD8<sup>+</sup> ratios may be very similar despite the individual being at different spectrums of HIV disease progression and thus, perhaps, at a different risk for MI (Figure 1). The approach used in this current study attempts to overcome this obstacle by making use of the actual T-cell counts. And it goes a step further by taking into account risk stratification for CD8<sup>+</sup> T cells based on clinically-relevant CD4<sup>+</sup> T-cell cut-points.

CD4<sup>+</sup> T-cell counts have long been established into clinically relevant cut-points [33]. HIV-infected persons with values  $\geq 500$  cells/mm<sup>3</sup> are considered closer to a “normal” immune status and experience fewer co-morbid conditions while those with values  $< 200$  cells/mm<sup>3</sup> are generally at a higher risk of co-morbid disease and have a severely compromised immune status. CD4<sup>+</sup> T-cell counts have thus been used as a proxy for the status of the immune system [33]. Harnessing these facts, an association of CD8<sup>+</sup> T-cell counts with MI risk is probably best viewed in the context of the person’s immune status. Indeed, these T-cell populations exhibit a dynamism that should be accounted for within the limits of clinical relevance and resources available to research.

When viewed in the context of baseline CD4<sup>+</sup> T-cell clinical cut-points, the MI risk associated with the CD8<sup>+</sup> T-cell count varied. Persons with a high CD8<sup>+</sup> T-cell count may be at most risk for MI events if with a CD4<sup>+</sup> T-cell count  $\geq 500$  cells/mm<sup>3</sup> or 200–499 cells/mm<sup>3</sup>. In contrast, when the CD4<sup>+</sup> T-cell count was low ( $< 200$  cells/mm<sup>3</sup>), the risk of MI appeared to be greatest among those persons with an equally low CD8<sup>+</sup> count ( $\leq 666$  cells/mm<sup>3</sup>).

The results from this present study do not disagree with the usefulness of CD4<sup>+</sup> T cells in determining the risk of comorbid disease in HIV. Rather they optimize its value in specifically determining the risk of MI in the setting of HIV. These findings were also consistent with the rates of MI observed in this cohort.

The reasons why MI risk associated with CD8<sup>+</sup> T-cell count differs depending on the status of the immune system are unclear at present, yet a potential explanation is presented here: HIV-infected individuals who do not have a low immune status (i.e. CD4<sup>+</sup> T cell counts  $\geq 500$  cells/mm<sup>3</sup> or 200–499 cells/mm<sup>3</sup>) appeared to be at greatest risk for MI if their baseline CD8<sup>+</sup> T-cell count was also high ( $\geq 1066$  cells/mm<sup>3</sup>). This may be a reflection of the damage to

endothelial cells and arterial walls due to increased amounts of pro-inflammatory cytokines and oxidative stress brought about by such high numbers of this cell type. The immune mechanisms behind the pathogenesis of atherosclerosis (a common precedent for MI) have been well-described in the literature [49].

That HIV-infected Veterans with a low immune status ( $CD4^+$  T-cell counts  $<200$  cells/mm<sup>3</sup>) appeared to be at greatest MI risk when their  $CD8^+$  T-cell count was also low ( $\leq 666$  cells/mm<sup>3</sup>) may not be entirely true. Proportional hazard models restricted to persons above and below the median age of approximately 50 years showed the pattern of  $CD8^+$  T-cell effect persisted in the older age group across all  $CD4^+$  T-cell strata; i.e. those  $\geq 50$  years of age had an increasing MI risk with increasing levels of  $CD8^+$  T cells. Some categories lacked statistical significance and this may be due to a reduction in statistical power from the stratification. Veterans below 50 years of age had a different  $CD8^+$  T-cell effect in the  $CD4^+$  T-cell  $<200$  cells/mm<sup>3</sup> stratum, which did not appear to follow a distinct pattern. This may be due to a relatively lower sample size in these  $CD8^+$  T-cell categories for persons in that  $CD4^+$  T-cell stratum, leading to a reduction in statistical power. In addition, this  $CD4^+$  T-cell stratum is associated with a severely compromised immune status: the competing risks of mortality from other comorbid conditions may have precluded the observance of MI events.

It should be noted that the effects of  $CD8^+$  T-cell levels appeared to have a larger effect size for the older age group in all  $CD4^+$  T-cell strata: With the exception of the  $CD4^+$  T-cell 200-499,  $CD8^+$  T-cell  $\leq 666$  cells/mm<sup>3</sup> group, more than 50% in each of the  $CD8^+$  T-cell categories were at greater MI risk than HIV-uninfected participants across all  $CD4^+$  T-cell strata compared to the younger age group. Whether a biological reason might be responsible for this is unclear at present.

In the regression model restricted to HIV-infected participants the trend of increasing MI risk with increasing CD8<sup>+</sup> T-cell level compared to the lowest CD8<sup>+</sup> tertile may have lacked statistical significance because of the reduced sample size (18,289) which potentially reduced statistical power. Less than half (258) of the 766 MI events observed were among HIV-infected Veterans. However, when CD8<sup>+</sup> T-cell count was treated as a continuous variable in the HIV-restricted model, it was observed that the risk of MI increased for every unit increase in CD8<sup>+</sup> T-cell count. This supports the findings from the previous results that MI risk does indeed appear to be greater with an increasing CD8<sup>+</sup> T-cell level. A linear relationship between CD8<sup>+</sup> T-cell counts and MI risk should not be necessarily assumed in this cohort however, as there was a wide range in the observed CD8<sup>+</sup> T-cell counts.

It should also be noted that the differences in the effect of CD8<sup>+</sup> T-cell counts appeared to be most marked in the group with CD4<sup>+</sup> T-cell levels of 200-499 cells/mm<sup>3</sup>. This effect was observed in all the regression models and reflected in the observed MI rates as well. This may indicate that that even though a high CD8<sup>+</sup> level is associated with an increased MI risk compared to uninfected persons, this relationship may be most useful in persons within this particular CD4<sup>+</sup> T-cell level. The violation of proportional hazards for the middle and low CD8<sup>+</sup> T-cell tertiles within the CD4<sup>+</sup>  $\geq 500$  cells/mm<sup>3</sup> category does not signify that the hazard ratios for these groups are non-informative. The ratios reveal the *average* effect for these groups, with the caveat that these ratios do not change proportionally with time. Moreover, proportional hazards regression models are often robust to slight changes in proportionality: it was observed that the non-proportionality appeared in the latter stages of the follow-up period (see log-log plot in Appendix).

This study confirmed that HIV-uninfected Veterans are at the least risk for MI as suggested by recent research [1]. It also showed that the risk of MI posed by traditional risk factors, demographic variables and other risk factors such as substance abuse, statin use and Hepatitis C virus infection virtually remained unchanged irrespective of whether the CD8<sup>+</sup> T-cell count was stratified by CD4<sup>+</sup> T-cell clinical cut-points or not. These factors should therefore be considered whenever assessing patients for MI risk.

In addition, this study compared rates of MI with HIV-uninfected persons as part of the study sample, utilized a large cohort and had clinically adjudicated MI outcomes. By making use of baseline CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts to determine MI risk, it also closely reproduced the setting in a physician clinic whereby reliable risk stratification for MI (or another comorbid disease) is often based on laboratory values obtained from that clinic visit.

The study had some limitations. It did not explore whether the changes in total CD8<sup>+</sup> T-cell counts were due to changes in HIV-specific CD8<sup>+</sup> T cells nor did it examine markers for CD8<sup>+</sup> T-cell immune activation, such as CD38<sup>+</sup>. However, it should be noted that these measures are often not available for routine clinic visits and are expensive.

Also, the stratification of the CD8<sup>+</sup> T-cell count into tertiles was arbitrary, being based on the cohort and not on pre-existing clinical cut-points. Interestingly, these tertile levels are very similar to those reported in other studies [2, 50]. Stratification of the CD8<sup>+</sup> T-cell count into tertiles enabled inclusion of HIV-uninfected Veterans into most of the analyses, through the creation of a “HIV-negative, no CD8<sup>+</sup> count” variable. But, because these uninfected persons did not have CD8<sup>+</sup> T-cell count measurements, the effects of CD8<sup>+</sup> T cells as a continuous variable could not be explored for them. The drawbacks of categorizing data include reduced statistical

power, reduced information, concealed non-linearity relationships and possibly even an increase in Type I error rates.

Another limitation was that time-updated covariates for CD8<sup>+</sup> (and CD4<sup>+</sup> T cells) were not used to determine MI risk. A time-updated model may have reflected the longitudinal changes in these two cell types and may have shown their relation with MI risk more clearly. Again, it should be stressed that this study was designed to simply determine associations between CD8<sup>+</sup> T-cell counts and MI risk, especially associations that would be of immediate relevance when making a clinical decision. Hence, while more accurate prediction of MI risk might have been achievable with a time-updated model or by taking into account measures of CD8<sup>+</sup> or CD4<sup>+</sup> T-cell nadirs, or recent CD8<sup>+</sup> or CD4<sup>+</sup> T-cell counts shortly before an MI event, in most clinic situations these parameters are not foreseeable when deciding patient care.

Yet another limitation was the demographic-makeup of the cohort: over 90% of the participants were male, so the study results may not be generalizable to females. Age-related factors may have also confounded the results. The proportional hazard model restricted to persons below the age of 50 years did not show a particular pattern of CD8<sup>+</sup> T-cell effect in the CD4<sup>+</sup> <200 cells/mm<sup>3</sup> group (as discussed earlier). Future studies could address these problems.

Additionally, while attempts were made to adjust for several known risk factors for MI, some confounding might still persist, especially with an ever-rapidly increasing number of non-traditional risk factors being discovered. However, traditional risk factors for MI still play a major role in its determination [34] and it is believed that adjusting for them, as in this study, will have done much to offset the effects of any residual confounding.

The all-cause mortality rates in the cohort showed that mortality increased with declining immune status and this may have posed some measure of competing-risk for the occurrence of



MI events. Mortality rates were most marked in the CD4<sup>+</sup> T-cell <200 cells/mm<sup>3</sup> category which may have affected the study findings in this category. Further research could resolve this issue.

Being a large study cohort, there may also be a limitation due to the presence of missing data. However, the multiple imputation techniques instituted appear to have handled this appropriately, for the observed MI rates were very similar to the estimated hazard ratios for CD8<sup>+</sup> T-cell count with and without stratification by CD4<sup>+</sup> T-cell count. Although the descriptive rates and also estimated risks of MI were found to have overlapping 95% confidence intervals, this does not necessarily make them equivalent to each other. Indeed, overlapping confidence intervals do not indicate that two or more rates (or risks) are not significantly different [51, 52]. Prior work on the association between CD8<sup>+</sup> T-cell subsets and AIDS progression has also revealed some overlap in the confidence intervals of the estimated hazard ratios [15]. Thus a reliance on *P* values for statistical significance alongside formal tests to differentiate between the various hazard-ratios may serve as a useful guide. Such interpretations should also take the sample size and statistical power into account. Tests of equality of the survivor function using Kaplan-Meier estimates showed that there was no statistically significant difference in survival experience between CD8<sup>+</sup> T-cell categories among HIV-infected persons, for each level of CD4<sup>+</sup> T-cells (see Appendix). Similarly, comparisons of hazard ratios within each CD4<sup>+</sup> T-cell level revealed that there was no statistically significant difference in MI risk between the CD8<sup>+</sup> categories (analyses not shown). More definitive studies may explain the reasons for this.

## 5.0 CONCLUSION

In conclusion, data from this longitudinal cohort study of Veterans confirm that MI risk is greater among HIV-infected compared to HIV-uninfected individuals. The results suggest that the CD8<sup>+</sup> T-cell count may be associated with an increased risk of MI, but the data are unclear. More specifically, the data would suggest that the CD8<sup>+</sup> T-cell count may need to be interpreted in the context of the CD4<sup>+</sup> T-cell count or overall immune status. They appear to be most informative when the individual has an immune status that is “near normal” (i.e. CD4<sup>+</sup> T-cell count 200-499 cells/mm<sup>3</sup>), with a high CD8<sup>+</sup> T-cell count being associated with greater MI risk. CD8<sup>+</sup> T-cell counts may help optimize CD4<sup>+</sup> T-cell clinical cut-points and may offer useful risk stratification for MI. They offer a potential means for improving HIV-patient care using resources already available in most clinic settings. As results from this study are not definitive, more research into the relationship between CD8<sup>+</sup> T-cell counts and MI is advised.

## APPENDIX: SUPPLEMENTAL TABLES AND FIGURES

**Table A.1. Missing Data for Baseline Variables of HIV-uninfected and HIV-infected**

### Veterans

<b>Covariate</b>	<b>Total (n, %)</b>	<b>HIV-uninfected (n, %)</b>	<b>HIV-infected (n, %)</b>
Gender	0	0	0
Race	0	0	0
Diabetes	0	0	0
Blood pressure	1,298 (1.77%)	1,141 (2.07%)	157 (0.86%)
HDL level	18,924 (25.78%)	14,856 (26.96%)	4,338 (23.72%)
LDL level	21,427 (29.19%)	16,546 (30.02%)	4,881 (26.69%)
TG level	15,115 (20.59%)	12,621 (22.90%)	2,494 (13.64%)
Statins use	0	0	0
Smoking history	5,223 (7.12%)	4,233 (7.68%)	990 (5.41%)
Hepatitis C status	0	0	0
eGFR category	7,714 (10.51%)	6,954 (12.62%)	7,714 (4.16%)
BMI $\geq 30$ kg/ m <sup>2</sup>	1,733 (2.36%)	1,570 (2.85%)	163 (0.89%)
Cocaine abuse	0	0	0
Alcohol abuse	0	0	0
Hemoglobin	9,911 (13.50%)	8,478 (15.38%)	1,433 (7.84%)
Baseline CD4 <sup>+</sup> TCL	1,690 (9.24%)	...	1,690 (9.24%)
Baseline VL	1,448 (7.92%)	...	1,448 (7.92%)
ART Regimen	0	...	0

Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; TG, Triglyceride; eGFR, estimated glomerular filtration rate; BMI, body mass index; TCL, T-cell level; VL, Viral load; ART, antiretroviral therapy.

**Table A.2. Number of Persons at Risk at Specific Time Points during the Follow-up Period  
(Risk Tables)**

**UNSTRATIFIED BY CD4<sup>+</sup> T-CELL LEVEL**

<b>Risk category</b>	<b>Time = 0 year</b>	<b>Time = 2 years</b>	<b>Time = 4 years</b>	<b>Time = 6 years</b>	<b>Time = 8 years</b>
HIV –	55,124	48,988	40,005	26,613	0
HIV+, CD8 <sup>+</sup> ≤666	5,988	4,965	3,797	2,564	0
HIV+, CD8 <sup>+</sup> 667-1065	6,191	5,516	4,516	3,242	0
HIV+, CD8 <sup>+</sup> ≥1066	6,121	5,498	4,486	3,264	0

**STRATIFIED BY CD4<sup>+</sup> T-CELL LEVEL**

<b>Risk category</b>	<b>Time = 0 year</b>	<b>Time = 2 years</b>	<b>Time = 4 years</b>	<b>Time = 6 years</b>	<b>Time = 8 years</b>
HIV –	55,124	48,988	40,005	26,613	0
<b>CD4<sup>+</sup> ≥500</b>					
HIV+, CD8 <sup>+</sup> ≤666	1,297	1,152	954	707	0
HIV+, CD8 <sup>+</sup> 667-1065	2,186	2,006	1,689	1,270	0
HIV+, CD8 <sup>+</sup> ≥1066	2,548	2,330	1,979	1,492	0
<b>CD4<sup>+</sup> 200-499</b>					
HIV+, CD8 <sup>+</sup> ≤666	2,137	1,883	1,523	1,081	0
HIV+, CD8 <sup>+</sup> 667-1065	2,686	2,410	1,981	1,425	0
HIV+, CD8 <sup>+</sup> ≥1066	2,580	2,313	1,856	1,366	0
<b>CD4<sup>+</sup> &lt;200</b>					
HIV+, CD8 <sup>+</sup> ≤666	2,554	1,930	1,320	776	0
HIV+, CD8 <sup>+</sup> 667-1065	1,319	1,100	846	547	0
HIV+, CD8 <sup>+</sup> ≥1066	993	855	651	406	0

\*All T-cell counts in cells/ mm<sup>3</sup>

Abbreviations used: HIV- , Human Immunodeficiency Virus uninfected; HIV+, Human Immunodeficiency Virus infected.

**Table A.3. Test statistics, Degrees of Freedom and *P* values for the Equality of the Survival Functions for various participant groups**

<b>Comparison Groups</b>	<b>Statistic<sup>a</sup></b>	<b>Value</b>	<b>df</b>	<b><i>P</i> value</b>
All 4 groups stratified by HIV status and CD8 <sup>+</sup> tertile	Tarone-Ware	35.05	3	<0.001
	Peto-Peto-Prentice	35.27	3	<0.001
For HIV+, CD8 <sup>+</sup> ≤666 cells/mm <sup>3</sup> compared with CD8 <sup>+</sup> 667-1065 cells/mm <sup>3</sup>	Tarone-Ware	0.00	1	0.9736 <sup>b</sup>
	Peto-Peto-Prentice	0.02	1	0.8793 <sup>b</sup>
For HIV+, CD8 <sup>+</sup> ≤666 cells/mm <sup>3</sup> compared with CD8 <sup>+</sup> ≥1065 cells/mm <sup>3</sup>	Tarone-Ware	1.13	1	0.2874 <sup>b</sup>
	Peto-Peto-Prentice	1.66	1	0.1971 <sup>b</sup>
For HIV+, CD8 <sup>+</sup> 667-1065 cells/mm <sup>3</sup> compared with CD8 <sup>+</sup> ≥1065 cells/mm <sup>3</sup>	Tarone-Ware	1.30	1	0.2549 <sup>b</sup>
	Peto-Peto-Prentice	1.42	1	0.2332 <sup>b</sup>
All 10 groups when participants were stratified by HIV status and CD8 <sup>+</sup> tertile for each CD4 <sup>+</sup> T-cell level	Tarone-Ware	42.22	9	<0.001
	Peto-Peto-Prentice	42.09	9	<0.001
All CD8 <sup>+</sup> tertiles, for HIV+ with CD4 <sup>+</sup> ≥ 500 cells/ mm <sup>3</sup>	Tarone-Ware	0.15	2	0.9281 <sup>b</sup>
	Peto-Peto-Prentice	0.31	2	0.8565 <sup>b</sup>
All CD8 <sup>+</sup> tertiles, for HIV+ with CD4 <sup>+</sup> 200-499 cells/ mm <sup>3</sup>	Tarone-Ware	5.04	2	0.0803 <sup>b</sup>
	Peto-Peto-Prentice	5.60	2	0.0609 <sup>b</sup>
All CD8 <sup>+</sup> tertiles, for HIV+ with CD4 <sup>+</sup> <200 cells/ mm <sup>3</sup>	Tarone-Ware	0.10	2	0.9497 <sup>b</sup>
	Peto-Peto-Prentice	0.20	2	0.9056 <sup>b</sup>

<sup>a</sup> The Tarone-Ware and Peto-Peto-Prentice tests were chosen because the Kaplan Meier curves of estimated survival function (Figures 3 and 4) showed late differences in survival experience.

<sup>b</sup> Bonferroni correction for alpha level of 0.0167 (i.e. 0.05/ 3) was used for these post-hoc comparisons.


Abbreviations used: HIV- , Human Immunodeficiency Virus uninfected; HIV+, Human Immunodeficiency Virus infected.

**Table A.4. Test statistics of Scaled Schoenfeld Residuals, Degrees of Freedom and *P* values for the tests of Proportional-Hazards assumptions for various proportional-hazards models using different functions of time**

<b>UNSTRATIFIED BY CD4<sup>+</sup> T-CELL LEVEL</b>									
<b>CD8<sup>+</sup> category</b>	<b>df</b>	<b>g(t) = t</b>		<b>g(t) = ln (t)</b>		<b>g(t) = <math>\hat{S}_{KM}(t)</math></b>		<b>g(t) = rank (t)</b>	
		<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>	<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>	<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>	<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>
HIV –	1	...	...	...	...	...	...	...	...
HIV+, CD8 <sup>+</sup> ≤666	1	1.86	0.1731	2.54	0.1111	1.54	0.2140	2.15	0.1428
HIV+, CD8 <sup>+</sup> 667-1065	1	0.37	0.5455	1.11	0.2923	0.23	0.6341	0.41	0.5196
HIV+, CD8 <sup>+</sup> ≥1066	1	0.38	0.5391	0.75	0.3850	0.46	0.4970	0.36	0.5513
<b>STRATIFIED BY CD4<sup>+</sup> T-CELL LEVEL</b>									
<b>Category</b>	<b>df</b>	<b>g(t) = t</b>		<b>g(t) = ln (t)</b>		<b>g(t) = <math>\hat{S}_{KM}(t)</math></b>		<b>g(t) = rank (t)</b>	
		<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>	<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>	<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>	<b>chi<sup>2</sup> value</b>	<b><i>P</i> value</b>
<b>CD4<sup>+</sup> ≥500</b>									
HIV+, CD8 <sup>+</sup> ≤666	1	5.75	0.0165	5.72	0.0168	5.52	0.0188	6.28	0.0122
HIV+, CD8 <sup>+</sup> 667-1065	1	6.46	0.0110	5.99	0.0144	5.90	0.0151	6.66	0.0098
HIV+, CD8 <sup>+</sup> ≥1066	1	1.89	0.1696	1.00	0.3177	2.15	0.1422	1.80	0.1800
<b>CD4<sup>+</sup> 200-499</b>									
HIV+, CD8 <sup>+</sup> ≤666	1	0.00	0.9773	0.19	0.6607	0.01	0.9285	0.01	0.6523
HIV+, CD8 <sup>+</sup> 667-1065	1	1.10	0.2947	0.18	0.6722	1.34	0.2465	1.04	0.3081
HIV+, CD8 <sup>+</sup> ≥1066	1	0.21	0.6463	0.60	0.4382	0.25	0.6168	0.20	0.6523
<b>CD4<sup>+</sup> &lt;200</b>									
HIV+, CD8 <sup>+</sup> ≤666	1	0.13	0.7157	0.13	0.7168	0.10	0.7567	0.15	0.6998
HIV+, CD8 <sup>+</sup> 667-1065	1	0.24	0.6273	0.03	0.8674	0.23	0.6304	0.23	0.6287
HIV+, CD8 <sup>+</sup> ≥1066	1	2.70	0.1006	0.61	0.4363	2.86	0.0909	2.62	0.1053

\*All T-cell counts in cells/mm<sup>3</sup>

Abbreviations used: t , time; ln (t) , natural logarithmic transformation of time;  $\hat{S}_{KM}(t)$  , Kaplan-Meier transformation of time; rank (t) , rank transformation of time; HIV- , Human Immunodeficiency Virus uninfected; HIV+ , Human Immunodeficiency Virus infected.



**Figure A.1. Log-log plot testing Proportional Hazards Assumptions for three HIV+, CD8<sup>+</sup> T-cell categories compared to the HIV-uninfected group.**

Abbreviations used: HIV- , HIV-uninfected; HIV+ , HIV-infected.

## BIBLIOGRAPHY

1. Freiberg, M.S., et al., *HIV Infection and the Risk of Acute Myocardial Infarction*. JAMA Intern Med, 2013: p. 1-9.
2. Lang, S., et al., *HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals*. Clin Infect Dis, 2012. **55**(4): p. 600-7.
3. Triant, V.A., J.B. Meigs, and S.K. Grinspoon, *Association of C-reactive protein and HIV infection with acute myocardial infarction*. J Acquir Immune Defic Syndr, 2009. **51**(3): p. 268-73.
4. Murphy, R. and D. Costagliola, *Increased cardiovascular risk in HIV infection: drugs, virus and immunity*. AIDS, 2008. **22**(13): p. 1625-7.
5. Friis-Moller, N., et al., *Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study*. Eur J Cardiovasc Prev Rehabil, 2010. **17**(5): p. 491-501.
6. Hunt, R. *Human Immunodeficiency Virus and AIDS – The Course of the Disease*. Microbiology and Immunology On-line [Web page] 2009 April 26, 2010 [cited 2013 March 25]; A description of the course of HIV, changes in immune cells and the development of AIDS. Available from: <http://pathmicro.med.sc.edu/lecture/hiv3.htm>.
7. Lang, W., et al., *Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS*. J Acquir Immune Defic Syndr, 1989. **2**(1): p. 63-9.
8. Lyles, R.H., et al., *Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study*. J Infect Dis, 2000. **181**(3): p. 872-80.
9. Streeck, H., et al., *Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells*. J Virol, 2009. **83**(15): p. 7641-8.
10. Margolick, J.B., et al., *Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest*



- regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr, 1993. 6(2): p. 153-61.*
11. Hazenberg, M.D., et al., *Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS, 2003. 17(13): p. 1881-8.*
  12. Mellors, J.W., et al., *Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med, 1997. 126(12): p. 946-54.*
  13. Detels, R., et al., *Patterns of CD4+ cell changes after HIV-1 infection indicate the existence of a codeterminant of AIDS. J Acquir Immune Defic Syndr, 1988. 1(4): p. 390-5.*
  14. Boutitie, F. and S.J. Pocock, *Predictive value of repeated measurements of CD4 lymphocyte counts on progression to AIDS. AIDS, 1994. 8(1): p. 35-41.*
  15. Giorgi, J.V., et al., *Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr, 1993. 6(8): p. 904-12.*
  16. Lo, J., et al., *Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS, 2010. 24(2): p. 243-53.*
  17. Kaplan, R.C., et al., *T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis, 2011. 203(4): p. 452-63.*
  18. Phillips, A.N., et al., *CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. AIDS, 1993. 7(7): p. 975-80.*
  19. Anderson, R.E., et al., *CD8+ T lymphocytes and progression to AIDS in HIV-infected men: some observations. AIDS, 1991. 5(2): p. 213-5.*
  20. Chevret, S., et al., *Prognostic value of an elevated CD8 lymphocyte count in HIV infection. Results of a prospective study of 152 asymptomatic HIV-positive individuals. AIDS, 1992. 6(11): p. 1349-52.*
  21. Fahey, J.L., et al., *The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med, 1990. 322(3): p. 166-72.*
  22. Durand, M., et al., *Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr, 2011. 57(3): p. 245-53.*

23. Triant, V.A., et al., *Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system*. *J Acquir Immune Defic Syndr*, 2010. **55**(5): p. 615-9.
24. Currier, J.S., et al., *Coronary heart disease in HIV-infected individuals*. *J Acquir Immune Defic Syndr*, 2003. **33**(4): p. 506-12.
25. Kvale, D., et al., *CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS*. *AIDS*, 1999. **13**(2): p. 195-201.
26. Justice, A.C., et al., *Veterans Aging Cohort Study (VACS): Overview and description*. *Med Care*, 2006. **44**(8 Suppl 2): p. S13-24.
27. Fultz, S.L., et al., *Development and verification of a "virtual" cohort using the National VA Health Information System*. *Med Care*, 2006. **44**(8 Suppl 2): p. S25-30.
28. Every, N.R., et al., *Quality Enhancement Research Initiative in ischemic heart disease: a quality initiative from the Department of Veterans Affairs. QUERI IHD Executive Committee*. *Med Care*, 2000. **38**(6 Suppl 1): p. I49-59.
29. Affairs, U.S.D.o.V. *VHA Medical SAS Datasets*. [Web Page] 2013 February 27, 2013 [cited 2013 March 25]; Resource for national administrative data on patient care encounters for health care provided by VHA. Available from: <http://www.virec.research.va.gov/MedSAS/Overview.htm>.
30. Ives, D.G., et al., *Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study*. *Ann Epidemiol*, 1995. **5**(4): p. 278-85.
31. Thygesen, K., et al., *Third universal definition of myocardial infarction*. *Circulation*, 2012. **126**(16): p. 2020-35.
32. Affairs, U.S.D.o.V. *Compensation and Pension Record Interchange (CAPRI)*. [Web Page] 2013 June 27, 2012 [cited 2013 March 25]; A portal to provide read-only access to individual patient electronic health records from all VA sites. Available from: <http://www.virec.research.va.gov/CAPRI-VistAWeb/CAPRI.htm>.
33. Centers for Disease Control and Prevention. *1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults*, in *MMWR Recomm Rep*1992. p. 1-19.
34. Boudi, F.B. and C.H. Ahsan. *Risk Factors for Coronary Artery Disease*. [Web Page] 1994-2013 January 30, 2012 [cited 2013 March 25]; Online resource for medical professionals. Available from: <http://emedicine.medscape.com/article/164163-overview#aw2aab6b2>.

35. Guallar, E., et al., *Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study*. BMC Public Health, 2011. **11**: p. 704.
36. Chobanian, A.V., et al., *The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report*. JAMA, 2003. **289**(19): p. 2560-72.
37. National Cholesterol Education Program Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in, *Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report*. Circulation, 2002. **106**(25): p. 3143-421.
38. Organization, W.H., *Obesity and Overweight Fact sheet No. 311*, in *WHO Media Centre2000*, Updated March 2013, World Health Organization: Geneva.
39. Foundation, N.K., *K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification*. Am J Kidney Dis., 2002. **39**(2 Suppl 1): p. S1-266.
40. Fasciano, N.J., et al., *Profile of Medicare beneficiaries with AIDS: application of an AIDS casefinding algorithm*. Health Care Financ Rev, 1998. **19**(3): p. 19-38.
41. Butt, A.A., et al., *Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection*. Hepatology, 2004. **40**(1): p. 115-119.
42. Kraemer, K.L., et al., *Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans*. Med Care, 2006. **44**(8 Suppl 2): p. S44-51.
43. Goulet, J.L., et al., *Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans*. AIDS, 2005. **19 Suppl 3**: p. S99-105.
44. Organization, W.H., *World prevalence of anaemia 1993-2005*. 2008, Geneva: World Health Organization.
45. Clayton, D.G., *Survival Analysis and Epidemiological Tables Reference Manual*. Release 12 ed. Stata(R), ed. StataCorp. 2011: Stata Press. p. 351-352.
46. Cox, D.R., *Regression Models and Life-Tables*. Journal of the Royal Statistical Society. Series B (Methodological), 1972. **34**(2): p. 187-220.
47. Cleves, M., et al., *An Introduction to Survival Analysis Using Stata*. Third ed. 2010, College Station, Texas: Stata Press.

48. Rubin, D.B., *Multiple Imputation after 18+ Years*. Journal of the American Statistical Association, 1996. **91**(434): p. 473-489.
49. Packard, R.R., A.H. Lichtman, and P. Libby, *Innate and adaptive immunity in atherosclerosis*. Semin Immunopathol, 2009. **31**(1): p. 5-22.
50. Pizzolo, G., et al., *Prognostic significance of soluble CD8 serum levels in HIV-1 infection*. AIDS, 1992. **6**(1): p. 133-4.
51. Wolfe, R. and J. Hanley, *If we're so different, why do we keep overlapping? When 1 plus 1 doesn't make 2*. CMAJ, 2002. **166**(1): p. 65-6.
52. Knezevic, A. *Overlapping Confidence Intervals and Statistical Significance*. StatNews #73. Cornell Statistical Consulting Unit Newsletter, 2008, Cornell University.